Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium

Christos E. Kyriakopoulos, Namita Chittoria, Toni K. Choueiri, Nils Kroeger, Jae Lyun Lee, Sandy Srinivas, Jennifer J. Knox, Georg A. Bjarnason, Scott D. Ernst, Lori A. Wood, Ulka N. Vaishampayan, Neeraj Agarwal, Sumanta K. Pal, Ravindran Kanesvaran, Sun Young Rha, Takeshi Yuasa, Frede Donskov, Scott A. North, Daniel Y. Heng, Brian I. Rini

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background Sarcomatoid renal cell carcinoma is associated with poor prognosis. Data regarding outcome in the targeted therapy era are lacking. Patients and Methods Clinical, prognostic, and treatment parameters in metastatic renal cell carcinoma patients with and without sarcomatoid histology treated with targeted therapy were retrospectively analyzed. Results Two thousand two hundred eighty-six patients were identified (sRCC: n = 230 and non-sRCC: n = 2056). sRCC patients had significantly worse IMDC prognostic criteria compared with non-sRCC (11% vs. 19% favorable risk; 49% vs. 57% intermediate risk, and 40% vs. 24% poor risk; P <.0001). Time from original diagnosis to relapse (excluding synchronous metastatic disease) was shorter in the sRCC group (18.8 vs. 42.9 months; P <.0001). There was no significant difference in the incidence of central nervous system metastases (6%-8%) or underlying clear cell histology (87%-88%). More than 93% of patients received VEGF inhibitors as first-line therapy; objective response was less common in sRCC whereas primary refractory disease was more common (21% vs. 26% and 43% vs. 21%; P <.0001, for both). sRCC patients had significantly less use of second- (P =.018) and third-line (P <.0001) systemic therapy. The median progression-free survival (PFS)/overall survival (OS) was 4.5/10.4 months in sRCC patients and 7.8/22.5 months in non-sRCC patients (P <.0001 for both). Sarcomatoid histology was associated with a significantly worse PFS and OS after adjusting for individual IMDC risk factors in multivariable analysis (hazard ratio, 1.5; P <.0001 for both). Conclusion Patients with sRCC have a shorter time to relapse, worse baseline prognostic criteria, and worse clinical outcome with targeted therapy. Additional insight into the biology of sRCC is needed to develop alternative therapeutics.

Original languageEnglish
Pages (from-to)e79-e85
JournalClinical Genitourinary Cancer
Volume13
Issue number2
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Renal Cell Carcinoma
Databases
Histology
Therapeutics
Disease-Free Survival
Recurrence
Survival
Vascular Endothelial Growth Factor A
Central Nervous System
Neoplasm Metastasis
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

Kyriakopoulos, Christos E. ; Chittoria, Namita ; Choueiri, Toni K. ; Kroeger, Nils ; Lee, Jae Lyun ; Srinivas, Sandy ; Knox, Jennifer J. ; Bjarnason, Georg A. ; Ernst, Scott D. ; Wood, Lori A. ; Vaishampayan, Ulka N. ; Agarwal, Neeraj ; Pal, Sumanta K. ; Kanesvaran, Ravindran ; Rha, Sun Young ; Yuasa, Takeshi ; Donskov, Frede ; North, Scott A. ; Heng, Daniel Y. ; Rini, Brian I. / Outcome of patients with metastatic sarcomatoid renal cell carcinoma : Results from the international metastatic renal cell carcinoma database consortium. In: Clinical Genitourinary Cancer. 2015 ; Vol. 13, No. 2. pp. e79-e85.
@article{45a3bd1eb438415d867a2f1f19953977,
title = "Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium",
abstract = "Background Sarcomatoid renal cell carcinoma is associated with poor prognosis. Data regarding outcome in the targeted therapy era are lacking. Patients and Methods Clinical, prognostic, and treatment parameters in metastatic renal cell carcinoma patients with and without sarcomatoid histology treated with targeted therapy were retrospectively analyzed. Results Two thousand two hundred eighty-six patients were identified (sRCC: n = 230 and non-sRCC: n = 2056). sRCC patients had significantly worse IMDC prognostic criteria compared with non-sRCC (11{\%} vs. 19{\%} favorable risk; 49{\%} vs. 57{\%} intermediate risk, and 40{\%} vs. 24{\%} poor risk; P <.0001). Time from original diagnosis to relapse (excluding synchronous metastatic disease) was shorter in the sRCC group (18.8 vs. 42.9 months; P <.0001). There was no significant difference in the incidence of central nervous system metastases (6{\%}-8{\%}) or underlying clear cell histology (87{\%}-88{\%}). More than 93{\%} of patients received VEGF inhibitors as first-line therapy; objective response was less common in sRCC whereas primary refractory disease was more common (21{\%} vs. 26{\%} and 43{\%} vs. 21{\%}; P <.0001, for both). sRCC patients had significantly less use of second- (P =.018) and third-line (P <.0001) systemic therapy. The median progression-free survival (PFS)/overall survival (OS) was 4.5/10.4 months in sRCC patients and 7.8/22.5 months in non-sRCC patients (P <.0001 for both). Sarcomatoid histology was associated with a significantly worse PFS and OS after adjusting for individual IMDC risk factors in multivariable analysis (hazard ratio, 1.5; P <.0001 for both). Conclusion Patients with sRCC have a shorter time to relapse, worse baseline prognostic criteria, and worse clinical outcome with targeted therapy. Additional insight into the biology of sRCC is needed to develop alternative therapeutics.",
author = "Kyriakopoulos, {Christos E.} and Namita Chittoria and Choueiri, {Toni K.} and Nils Kroeger and Lee, {Jae Lyun} and Sandy Srinivas and Knox, {Jennifer J.} and Bjarnason, {Georg A.} and Ernst, {Scott D.} and Wood, {Lori A.} and Vaishampayan, {Ulka N.} and Neeraj Agarwal and Pal, {Sumanta K.} and Ravindran Kanesvaran and Rha, {Sun Young} and Takeshi Yuasa and Frede Donskov and North, {Scott A.} and Heng, {Daniel Y.} and Rini, {Brian I.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.clgc.2014.08.011",
language = "English",
volume = "13",
pages = "e79--e85",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "2",

}

Kyriakopoulos, CE, Chittoria, N, Choueiri, TK, Kroeger, N, Lee, JL, Srinivas, S, Knox, JJ, Bjarnason, GA, Ernst, SD, Wood, LA, Vaishampayan, UN, Agarwal, N, Pal, SK, Kanesvaran, R, Rha, SY, Yuasa, T, Donskov, F, North, SA, Heng, DY & Rini, BI 2015, 'Outcome of patients with metastatic sarcomatoid renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium', Clinical Genitourinary Cancer, vol. 13, no. 2, pp. e79-e85. https://doi.org/10.1016/j.clgc.2014.08.011

Outcome of patients with metastatic sarcomatoid renal cell carcinoma : Results from the international metastatic renal cell carcinoma database consortium. / Kyriakopoulos, Christos E.; Chittoria, Namita; Choueiri, Toni K.; Kroeger, Nils; Lee, Jae Lyun; Srinivas, Sandy; Knox, Jennifer J.; Bjarnason, Georg A.; Ernst, Scott D.; Wood, Lori A.; Vaishampayan, Ulka N.; Agarwal, Neeraj; Pal, Sumanta K.; Kanesvaran, Ravindran; Rha, Sun Young; Yuasa, Takeshi; Donskov, Frede; North, Scott A.; Heng, Daniel Y.; Rini, Brian I.

In: Clinical Genitourinary Cancer, Vol. 13, No. 2, 01.04.2015, p. e79-e85.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Outcome of patients with metastatic sarcomatoid renal cell carcinoma

T2 - Results from the international metastatic renal cell carcinoma database consortium

AU - Kyriakopoulos, Christos E.

AU - Chittoria, Namita

AU - Choueiri, Toni K.

AU - Kroeger, Nils

AU - Lee, Jae Lyun

AU - Srinivas, Sandy

AU - Knox, Jennifer J.

AU - Bjarnason, Georg A.

AU - Ernst, Scott D.

AU - Wood, Lori A.

AU - Vaishampayan, Ulka N.

AU - Agarwal, Neeraj

AU - Pal, Sumanta K.

AU - Kanesvaran, Ravindran

AU - Rha, Sun Young

AU - Yuasa, Takeshi

AU - Donskov, Frede

AU - North, Scott A.

AU - Heng, Daniel Y.

AU - Rini, Brian I.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background Sarcomatoid renal cell carcinoma is associated with poor prognosis. Data regarding outcome in the targeted therapy era are lacking. Patients and Methods Clinical, prognostic, and treatment parameters in metastatic renal cell carcinoma patients with and without sarcomatoid histology treated with targeted therapy were retrospectively analyzed. Results Two thousand two hundred eighty-six patients were identified (sRCC: n = 230 and non-sRCC: n = 2056). sRCC patients had significantly worse IMDC prognostic criteria compared with non-sRCC (11% vs. 19% favorable risk; 49% vs. 57% intermediate risk, and 40% vs. 24% poor risk; P <.0001). Time from original diagnosis to relapse (excluding synchronous metastatic disease) was shorter in the sRCC group (18.8 vs. 42.9 months; P <.0001). There was no significant difference in the incidence of central nervous system metastases (6%-8%) or underlying clear cell histology (87%-88%). More than 93% of patients received VEGF inhibitors as first-line therapy; objective response was less common in sRCC whereas primary refractory disease was more common (21% vs. 26% and 43% vs. 21%; P <.0001, for both). sRCC patients had significantly less use of second- (P =.018) and third-line (P <.0001) systemic therapy. The median progression-free survival (PFS)/overall survival (OS) was 4.5/10.4 months in sRCC patients and 7.8/22.5 months in non-sRCC patients (P <.0001 for both). Sarcomatoid histology was associated with a significantly worse PFS and OS after adjusting for individual IMDC risk factors in multivariable analysis (hazard ratio, 1.5; P <.0001 for both). Conclusion Patients with sRCC have a shorter time to relapse, worse baseline prognostic criteria, and worse clinical outcome with targeted therapy. Additional insight into the biology of sRCC is needed to develop alternative therapeutics.

AB - Background Sarcomatoid renal cell carcinoma is associated with poor prognosis. Data regarding outcome in the targeted therapy era are lacking. Patients and Methods Clinical, prognostic, and treatment parameters in metastatic renal cell carcinoma patients with and without sarcomatoid histology treated with targeted therapy were retrospectively analyzed. Results Two thousand two hundred eighty-six patients were identified (sRCC: n = 230 and non-sRCC: n = 2056). sRCC patients had significantly worse IMDC prognostic criteria compared with non-sRCC (11% vs. 19% favorable risk; 49% vs. 57% intermediate risk, and 40% vs. 24% poor risk; P <.0001). Time from original diagnosis to relapse (excluding synchronous metastatic disease) was shorter in the sRCC group (18.8 vs. 42.9 months; P <.0001). There was no significant difference in the incidence of central nervous system metastases (6%-8%) or underlying clear cell histology (87%-88%). More than 93% of patients received VEGF inhibitors as first-line therapy; objective response was less common in sRCC whereas primary refractory disease was more common (21% vs. 26% and 43% vs. 21%; P <.0001, for both). sRCC patients had significantly less use of second- (P =.018) and third-line (P <.0001) systemic therapy. The median progression-free survival (PFS)/overall survival (OS) was 4.5/10.4 months in sRCC patients and 7.8/22.5 months in non-sRCC patients (P <.0001 for both). Sarcomatoid histology was associated with a significantly worse PFS and OS after adjusting for individual IMDC risk factors in multivariable analysis (hazard ratio, 1.5; P <.0001 for both). Conclusion Patients with sRCC have a shorter time to relapse, worse baseline prognostic criteria, and worse clinical outcome with targeted therapy. Additional insight into the biology of sRCC is needed to develop alternative therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84924619957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924619957&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2014.08.011

DO - 10.1016/j.clgc.2014.08.011

M3 - Article

C2 - 25450036

AN - SCOPUS:84924619957

VL - 13

SP - e79-e85

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 2

ER -